News 23.04.19

Voucher gives rise to collaboration

Synaffix has developed a new technology for targeted anti-cancer therapy. Specifically, Synaffix has improved the therapeutic window of an antibody-drug...

Read more
News 11.04.19

Synaffix Announces License Agreement worth up to $125 million with Leading Chinese ADC Developer, Shanghai Miracogen

Synaffix B.V., a Dutch biotechnology company exclusively focused on continued advancement of its clinical-stage antibody-drug conjugate (ADC) technology for the...

Read more
News 09.04.19

New at Pivot Park – Absano

AbSano develops novel antibodies for innovative diagnostic tools as well as therapeutic purposes. “Our current projects involve the identification and...

Read more
News 08.04.19

BioConnection invests in expansion of its current production capacity with a second production line

BioConnection will invest €12 million in a second, commercial scale, manufacturing line to keep up with the growing customer demand...

Read more
News 05.04.19

A cup of coffee with….Lonneke Meijerink (Pivot Park)

Since March Lonneke started working at the Pivot Park Site Organisation as financial accountant. “After studying Business Economics at Tilburg...

Read more
News 01.04.19

Phio and Glycostem to Collaborate on Use of its sd-rxRNA® platform and Glycostem’s oNKord® Cell Therapy Products for the Next Generation of Natural Killer Cell-based Immunotherapy for Cancer Treatment

Phio Pharmaceuticals Corp. (NASDAQ: PHIO) announced today that it has entered into a research collaboration with Glycostem Therapeutics BV to explore the potential synergies of using Phio's self-delivering RNAi technology (sd-rxRNA®) in combination with Glycostem's proprietary Natural Killer-cell (NK-cell) generation technology (oNKord®) to develop cellular immunotherapies for cancer treatment with enhanced efficacy and/or safety.

Read more
News 29.03.19

Pharming announces a provisional commitment to invest in a minority stake in its fill & finish partner BioConnection BV

Pharming Group N.V. announces that it has made a provisional commitment to invest up to €1.6 million in cash and...

Read more
News 28.03.19

NTRC and Radboud explore new methods to predict chemotherapy response in ovarian cancer

NTRC and Radboudumc Nijmegen (The Netherlands) are developing a platform to predict the response of high-grade serous ovarian cancer patients to chemotherapy by using tumor and immune cells isolated at diagnosis. While patients receive normal standard-of-care treatment, data are collected to improve future diagnostics and care.

Read more
News 25.03.19

Lead Pharma Announces Start of Phase I Clinical Trials with SAR441169 Candidate Treatment for Psoriasis

Sanofi, Lead Pharma’s collaborative partner in the development of SAR441169, successfully initiated first human dosing with this novel RORγt Inverse Agonist...

Read more